All In Biotech

Drug Trial Radar · NCT04646759

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer: A Multicenter, Randomized, Phase III Study

Last checked: Nov 19, 2026Latest source record: Nov 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 516 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

516

Planned (sponsor's estimate)

Start

Oct 14, 2020

Primary completion

Dec 14, 2028

Study completion Dec 14, 2030

Sponsor

Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and HER2 inhibitor pyrotinib have a synergistic effect. The preliminary analysis of our prospective shows that the efficacy is close to that of capecitabine combined with pyrotinib, and the adverse events are significantly improved compared with capecitabine combined with pyrotinib. Therefore, it is necessary to further carry out a head-to-head phase III randomized controlled clinical trial to study the efficacy and safety of fulvestrant combined with pyrotinib in the treatment of HR + / HER2 + advanced breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Fulvestrant combined with PyrotinibDrug

    Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily

  • Capecitabine combined with PyrotinibDrug

    Capecitabine 1000mg/m\^2 bid d1-d14,every 21 days Pyrotinib 400mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 24 months
  2. Incidence of grade 3 hand foot syndrome (rate)Time frame: From the date of enrollment to one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.